UCB Logo

UCB

ISIN: BE0003739530 | Ticker: UCB | LEI: 2138008J191VLSGY5A09
Sector: Health CareSub-Industry: Pharmaceuticals
Country: Belgium

About UCB

Company Description

A global biopharma company, inspired by the needs of people living with severe diseases.

At UCB, we are consistently delivering on our commitment to improve the lives of people living with severe neurological and immunological conditions. And thanks to our focused, innovative and trusted solutions, our business is strong.

Our people have lived our purpose each day since 1928, making critical investments in biopharmaceutical research and leading innovations that strive to achieve a meaningful impact on the lives of those we serve.

UCB’s ambition is to transform the lives of people living with severe diseases, allowing them to live the best life that they can – as free as possible from the challenges and uncertainty of disease. That commitment comes to life in our research and development activities across neurology, immunology and other areas where our expertise, innovation and ambition align with unmet needs.

Year founded

1928

Served area

Worldwide

Headcount

8,600

Headquarters

Allée de la Recherche 60, 1070 Bruxelles, Bruxelles-Capitale – Belgium

Financial statements

Download as Excel
Line item in (eur) 01.01.2020 01.01.2021 01.01.2022
Assets N/A 13,319,000,000.00 14,210,000,000.00
Noncurrent Assets N/A 9,737,000,000.00 10,500,000,000.00
Property Plant And Equipment N/A 1,035,000,000.00 1,275,000,000.00
Goodwill N/A 4,964,000,000.00 5,173,000,000.00
Intangible Assets Other Than Goodwill N/A 2,973,000,000.00 3,159,000,000.00
Deferred Tax Assets N/A 605,000,000.00 692,000,000.00
Current Assets N/A 3,582,000,000.00 3,710,000,000.00
Inventories N/A 854,000,000.00 878,000,000.00
Trade And Other Current Receivables N/A 1,031,000,000.00 1,239,000,000.00
Current Tax Assets Current N/A 48,000,000.00 51,000,000.00
Cash and cash equivalents N/A 1,336,000,000.00 1,263,000,000.00
Noncurrent Assets Or Disposal Groups Classified As Held For Sale N/A 3,000,000.00 6,000,000.00
Equity And Liabilities N/A 13,319,000,000.00 14,210,000,000.00
Equity 7,009,000,000.00 7,272,000,000.00 8,386,000,000.00
Equity Attributable To Owners Of Parent N/A 7,271,000,000.00 8,386,000,000.00
Noncontrolling Interests N/A 1,000,000.00 0.00
Liabilities N/A 6,047,000,000.00 5,824,000,000.00
Noncurrent Liabilities N/A 3,233,000,000.00 3,000,000,000.00
Noncurrent Provisions For Employee Benefits N/A 402,000,000.00 315,000,000.00
Other Longterm Provisions N/A 165,000,000.00 188,000,000.00
Noncurrent Payables N/A 91,000,000.00 86,000,000.00
Deferred Tax Liabilities N/A 168,000,000.00 191,000,000.00
Current Tax Liabilities Noncurrent N/A 88,000,000.00 139,000,000.00
Other Noncurrent Financial Liabilities N/A 3,000,000.00 13,000,000.00
Longterm Borrowings N/A 1,629,000,000.00 1,252,000,000.00
Noncurrent Portion Of Noncurrent Bonds Issued N/A 687,000,000.00 816,000,000.00
Current Liabilities N/A 2,814,000,000.00 2,824,000,000.00
Other Shortterm Provisions N/A 80,000,000.00 83,000,000.00
Trade And Other Current Payables N/A 2,138,000,000.00 2,555,000,000.00
Current Tax Liabilities Current N/A 79,000,000.00 31,000,000.00
Other Current Financial Liabilities N/A 86,000,000.00 100,000,000.00
Liabilities Included In Disposal Groups Classified As Held For Sale N/A 0.00 0.00
Current Borrowings And Current Portion Of Noncurrent Borrowings N/A 81,000,000.00 55,000,000.00
Current Bonds Issued And Current Portion Of Noncurrent Bonds Issued N/A 350,000,000.00 0.00
Line item in (eur) 01.01.2020/
01.01.2021
01.01.2021/
01.01.2022
Revenue 5,347,000,000.00 5,777,000,000.00
Revenue From Sale Of Goods 5,052,000,000.00 5,471,000,000.00
Revenue From Royalties 96,000,000.00 79,000,000.00
Other Revenue 199,000,000.00 227,000,000.00
Other Gains Losses -102,000,000.00 -7,000,000.00
Profit Loss From Operating Activities 971,000,000.00 1,284,000,000.00
Finance Income 14,000,000.00 80,000,000.00
Finance Costs 107,000,000.00 138,000,000.00
Profit Loss Before Tax 880,000,000.00 1,226,000,000.00
Income Tax Expense Continuing Operations 119,000,000.00 170,000,000.00
Profit Loss From Continuing Operations 761,000,000.00 1,056,000,000.00
Profit Loss From Discontinued Operations 0.00 3,000,000.00
Profit (loss) 761,000,000.00 1,058,000,000.00
Profit Loss Attributable To Owners Of Parent 732,000,000.00 1,058,000,000.00
Profit Loss Attributable To Noncontrolling Interests 29,000,000.00 0.00
Line item in (eur) 01.01.2021 01.01.2022
Profit (loss) 761,000,000.00 1,058,000,000.00
Adjustments For Undistributed Profits Of Associates 2,000,000.00 0.00
Other Adjustments For Noncash Items 297,000,000.00 239,000,000.00
Other Adjustments For Which Cash Effects Are Investing Or Financing Cash Flow 2,000,000.00 41,000,000.00
Other Adjustments To Reconcile Profit Loss -263,000,000.00 0.00
Cash Flows From Used In Operations 1,153,000,000.00 1,679,000,000.00
Interest Received Classified As Operating Activities 17,000,000.00 17,000,000.00
Income Taxes Paid Refund Classified As Operating Activities 72,000,000.00 126,000,000.00
Other Inflows Outflows Of Cash Classified As Operating Activities 119,000,000.00 170,000,000.00
Cash Flows From Used In Operating Activities 1,081,000,000.00 1,553,000,000.00
Cash Flows Used In Obtaining Control Of Subsidiaries Or Other Businesses Classified As Investing Activities 1,986,000,000.00 0.00
Proceeds From Sales Of Property Plant And Equipment Classified As Investing Activities 1,000,000.00 1,000,000.00
Purchase Of Property Plant And Equipment Classified As Investing Activities 256,000,000.00 282,000,000.00
Purchase Of Intangible Assets Classified As Investing Activities 93,000,000.00 211,000,000.00
Purchase Of Other Longterm Assets Classified As Investing Activities 7,000,000.00 19,000,000.00
Other Inflows Outflows Of Cash Classified As Investing Activities 75,000,000.00 15,000,000.00
Cash Flows From Used In Investing Activities -2,228,000,000.00 -487,000,000.00
Payments To Acquire Or Redeem Entitys Shares 106,000,000.00 60,000,000.00
Proceeds From Borrowings Classified As Financing Activities 1,895,000,000.00 0.00
Repayments Of Borrowings Classified As Financing Activities 166,000,000.00 512,000,000.00
Payments Of Lease Liabilities Classified As Financing Activities 41,000,000.00 40,000,000.00
Dividends Paid Classified As Financing Activities 235,000,000.00 240,000,000.00
Interest Paid Classified As Financing Activities 70,000,000.00 63,000,000.00
Cash Flows From Used In Financing Activities 1,177,000,000.00 -1,119,000,000.00
Increase (decrease) in cash and cash equivalents before effect of exchange rate changes 30,000,000.00 -53,000,000.00
Effect Of Exchange Rate Changes On Cash And Cash Equivalents -15,000,000.00 -7,000,000.00
Cash and cash equivalents 1,336,000,000.00 1,263,000,000.00

Please note that some sums might not add up.

Filings & Publications

2021

Report
Q1
H1
Q3
FY
Consolidated Report
NLD / ENG / FRA
Corporate Governance Report
Company Presentation
Sustainability Report
Remuneration Report

Insider Trades

Date Trading entity / Person Association Trade type Volume
18.01.24 Loew-Friedrich Iris Executive member Buy EUR 329,307.92
15.01.24 Loew-Friedrich Iris Executive member Buy EUR 290,600.00
12.01.24 Loew-Friedrich Iris Executive member Sell EUR 420,000.00
12.01.24 Loew-Friedrich Iris Executive member Buy EUR 290,600.00
11.01.24 Johnson Waynick Denelle Executive member Buy EUR 10,490.74
15.12.23 ALTAI INVEST Close relation Buy EUR 988,983.00
27.10.23 Janssen Charles-Antoine Board Buy EUR 104,332.20
24.10.23 Peacock Jonathan Board Buy USD 98,350.20
20.10.23 ALTAI INVEST Close relation Buy EUR 997,889.54
20.10.23 du Monceau de Bergendal Fiona Board Buy EUR 198,184.00

Capital markets information

ISIN

BE0003739530

LEI

2138008J191VLSGY5A09

Sector

Health Care

Industry Group

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Pharmaceuticals

Sub-Industry

Pharmaceuticals

Listed Stock Exchange

Euronext Brussels

Stock Index

BEL20

Main Stock Exchange

Contact Investor Relations department

Stay up to date

Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.